Brendan Kennedy – Head of the 3D-NEONET Industry – Academia consortium

    • Brendan Kennedy – Head of the 3D-NEONET Industry – Academia consortium's presentations

    Prof.  Breandán Kennedy is head of the 3D-NEONET Industry – Academia consortium. He is Professor of Pharmacology in University College Dublin. and a Research Fellow of the Conway Institute at UCD. The main objective of Breandán’s research group is to develop gene and pharmacological treatments for human blindness. Using zebrafish as an in vivo system, his group identified several families with inherited blindness and have used these to characterise disease progression and evaluate therapies.  They have also developed in vivo assays enabling us to discover novel drugs with specific neuroprotectant, anti-angiogenic or toxic properties in the eye. Technology platforms include: zebrafish: development, expression profiling, genetics,transgenics, morphants and drug screens; Retina: Morphology and Function.



    Title: Zebrafish are an effective model for discovery and development of drugs for blindness and cancer

     Synopsis: Discovery of ocular and oncology therapeutics typically relies on reductionist approaches to a small number of targets known to regulate physiological or pathological processes. A preferential approach utilises an unbiased screen of drug libraries to identify drugs that restore/maintain visual function or inhibit disease pathologies as primary phenotypic end-points. Here, we provide a critical analysis of our phenotype-based drug screens in zebrafish which discover drugs improving visual function or inhibiting angiogenesis in vivo. In conclusion, phenotype-based drug screening in zebrafish provides exciting opportunities to identify existing drugs which can be re-purposed, or novel first-in-class drugs for development as therapeutics for blindness or cancer.